Browsing by Author "Doruyter, Alex"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Appropriate indications for positron emission tomography/computed tomography : College of Nuclear Physicians of the Colleges of Medicine of South Africa
    (Health & Medical Publishing Group, 2016) Sathekge, Mike; Warwick, James M.; Doruyter, Alex; Vorster, Mariza
    Individualised patient treatment approaches demand precise determination of initial disease extent combined with early, accurate assessment of response to treatment, which is made possible by positron emission tomography/computed tomography (PET/CT). PET is a non-invasive tool that provides tomographic images and quantitative parameters of perfusion, cell viability, and proliferation and/or metabolic activity of tissues. Fusion of the functional information with the morphological detail provided by CT as PET/CT can provide clinicians with a sensitive and accurate one-step whole-body diagnostic and prognostic tool, which directs and changes patient management. Three large-scale national studies published by the National Oncologic PET Registry in the USA have shown that imaging with PET changes the intended patient management strategy in 36.5% to 49% of cases, with consistent results across all cancer types. The proven clinical effectiveness and growing importance of PET/CT have prompted the College of Nuclear Physicians of South Africa, in collaboration with university hospitals, to develop a list of recommendations on the appropriate use of fluorine-18-fluorodeoxyglucose (18F-FDG) and non-18F-FDG PET/CT in oncology, cardiology, neurology and infection/inflammation. It is expected that other clinical situations will be added to these recommendations, provided that they are based upon solid clinical evidence. These recommendations are intended to offer advice regarding contemporary applications of PET/CT, as well as indicating novel developments and potential future indications. The CNP believes that these recommendations will serve an important and relevant role in advising referring physicians on the appropriate use of 18F-FDG and non-18F-FDG PET/CT. More promising clinical applications will be possible in the future, as newer PET tracers become more readily available.
  • Thumbnail Image
    Item
    Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response
    (SpringerOpen (part of Springer Nature), 2020-02-10) Malherbe, Stephanus T.; Chen, Ray Y.; Dupont, Patrick; Kant, Ilse; Kriel, Magdalena; Loxton, Andre G.; Smith, Bronwyn; Beltran, Caroline G. G.; Van Zyl, Susan; McAnda, Shirely; Abrahams, Charmaine; Maasdorp, Elizna; Doruyter, Alex; Via, Laura E.; Barry, Clifton E.; Alland, David; Richards, Stephanie G.; Ellman, Annare; Peppard, Thomas; Belisle, John; Tromp, Gerard; Ronacher, Katharina; Warwick, James M.; Winter, Jill; Walzl, Gerhard
    Background: There is a growing interest in the use of F-18 FDG PET-CT to monitor tuberculosis (TB) treatment response. Tuberculosis lung lesions are often complex and diffuse, with dynamic changes during treatment and persisting metabolic activity after apparent clinical cure. This poses a challenge in quantifying scan-based markers of burden of disease and disease activity. We used semi-automated, whole lung quantification of lung lesions to analyse serial FDG PET-CT scans from the Catalysis TB Treatment Response Cohort to identify characteristics that best correlated with clinical and microbiological outcomes. Results: Quantified scan metrics were already associated with clinical outcomes at diagnosis and 1 month after treatment, with further improved accuracy to differentiate clinical outcomes after standard treatment duration (month 6). A high cavity volume showed the strongest association with a risk of treatment failure (AUC 0.81 to predict failure at diagnosis), while a suboptimal reduction of the total glycolytic activity in lung lesions during treatment had the strongest association with recurrent disease (AUC 0.8 to predict pooled unfavourable outcomes). During the first year after TB treatment lesion burden reduced; but for many patients, there were continued dynamic changes of individual lesions. Conclusions: Quantification of FDG PET-CT images better characterised TB treatment outcomes than qualitative scan patterns and robustly measured the burden of disease. In future, validated metrics may be used to stratify patients and help evaluate the effectiveness of TB treatment modalities.
  • Thumbnail Image
    Item
    Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response
    (SpringerOpen (part of Springer Nature), 2020) Malherbe, Stephanus T.; Chen, Ray Y.; Dupont, Patrick; Kant, Ilse; Kriel, Magdalena; Loxton, Andre G.; Smith, Bronwyn; Beltran, Caroline G. G.; Van Zyl, Susan; McAnda, Shirely; Abrahams, Charmaine; Maasdorp, Elizna; Doruyter, Alex; Via, Laura E.; Barry, Clifton E.; Alland, David; Griffith- Richards, Stephanie; Ellman, Annare; Peppard, Thomas; Belisle, John; Tromp, Gerard; Ronacher, Katharina; Warwick, James M.; Winter, Jill; Walzl, Gerhard
    Background: There is a growing interest in the use of F-18 FDG PET-CT to monitor tuberculosis (TB) treatment response. Tuberculosis lung lesions are often complex and diffuse, with dynamic changes during treatment and persisting metabolic activity after apparent clinical cure. This poses a challenge in quantifying scan-based markers of burden of disease and disease activity. We used semi-automated, whole lung quantification of lung lesions to analyse serial FDG PET-CT scans from the Catalysis TB Treatment Response Cohort to identify characteristics that best correlated with clinical and microbiological outcomes. Results: Quantified scan metrics were already associated with clinical outcomes at diagnosis and 1 month after treatment, with further improved accuracy to differentiate clinical outcomes after standard treatment duration (month 6). A high cavity volume showed the strongest association with a risk of treatment failure (AUC 0.81 to predict failure at diagnosis), while a suboptimal reduction of the total glycolytic activity in lung lesions during treatment had the strongest association with recurrent disease (AUC 0.8 to predict pooled unfavourable outcomes). During the first year after TB treatment lesion burden reduced; but for many patients, there were continued dynamic changes of individual lesions. Conclusions: Quantification of FDG PET-CT images better characterised TB treatment outcomes than qualitative scan patterns and robustly measured the burden of disease. In future, validated metrics may be used to stratify patients and help evaluate the effectiveness of TB treatment modalities.